Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.

Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN.

Cell. 2018 Nov 15;175(5):1443. doi: 10.1016/j.cell.2018.11.003. No abstract available.

2.

High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.

Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN.

Cell. 2018 Nov 1;175(4):1014-1030.e19. doi: 10.1016/j.cell.2018.09.030. Epub 2018 Oct 18. Erratum in: Cell. 2018 Nov 15;175(5):1443.

PMID:
30343900
3.

Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection.

Sheehan KC, Lazear HM, Diamond MS, Schreiber RD.

PLoS One. 2015 May 26;10(5):e0128636. doi: 10.1371/journal.pone.0128636. eCollection 2015.

4.

Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection.

Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, Sheehan KC, Schreiber RD, Oldstone MB.

Cell Host Microbe. 2015 May 13;17(5):653-61. doi: 10.1016/j.chom.2015.04.005.

5.

Loss of DAP12 and FcRγ drives exaggerated IL-12 production and CD8(+) T cell response by CCR2(+) Mo-DCs.

Gmyrek GB, Akilesh HM, Graham DB, Fuchs A, Yang L, Miller MJ, Sandoval GJ, Sheehan KC, Schreiber RD, Diamond MS, Swat W.

PLoS One. 2013 Oct 14;8(10):e76145. doi: 10.1371/journal.pone.0076145. eCollection 2013.

6.

Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-γ receptor subunit 1 (IFNGR1).

Lee SH, Carrero JA, Uppaluri R, White JM, Archambault JM, Lai KS, Chan SR, Sheehan KC, Unanue ER, Schreiber RD.

J Immunol. 2013 Oct 15;191(8):4223-34. doi: 10.4049/jimmunol.1300910. Epub 2013 Sep 18.

7.

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Chan SR, Rickert CG, Vermi W, Sheehan KC, Arthur C, Allen JA, White JM, Archambault J, Lonardi S, McDevitt TM, Bhattacharya D, Lorenzi MV, Allred DC, Schreiber RD.

Cell Death Differ. 2014 Feb;21(2):234-46. doi: 10.1038/cdd.2013.116. Epub 2013 Sep 13.

8.

Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB.

Science. 2013 Apr 12;340(6129):207-11. doi: 10.1126/science.1235214.

9.

A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection.

Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, Murphy KM, Schreiber RD, Diamond MS.

PLoS Pathog. 2011 Dec;7(12):e1002407. doi: 10.1371/journal.ppat.1002407. Epub 2011 Dec 1.

10.

A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice.

Miller JC, Ma Y, Bian J, Sheehan KC, Zachary JF, Weis JH, Schreiber RD, Weis JJ.

J Immunol. 2008 Dec 15;181(12):8492-503.

11.

Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody.

Uppaluri R, Sheehan KC, Wang L, Bui JD, Brotman JJ, Lu B, Gerard C, Hancock WW, Schreiber RD.

Transplantation. 2008 Jul 15;86(1):137-47. doi: 10.1097/TP.0b013e31817b8e4b.

12.

Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.

Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KC, Capron M, Ryffel B, Faveeuw C, Leite de Moraes M, Platt F, Trottein F.

Immunity. 2007 Oct;27(4):597-609. Epub 2007 Oct 18.

13.

Type I IFN contributes to NK cell homeostasis, activation, and antitumor function.

Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ.

J Immunol. 2007 Jun 15;178(12):7540-9.

14.

Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection.

Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD.

J Interferon Cytokine Res. 2006 Nov;26(11):804-19.

PMID:
17115899
15.

The hand that rocks the cradle.

Sheehan KC.

Univ Toledo Law Rev. 2001 Winter;32(2):229-47.

PMID:
16485368
16.

Interferon-gamma and cancer immunoediting.

Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD.

Immunol Res. 2005;32(1-3):231-45. Review.

PMID:
16106075
17.

A critical function for type I interferons in cancer immunoediting.

Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD.

Nat Immunol. 2005 Jul;6(7):722-9. Epub 2005 Jun 12. Erratum in: Nat Immunol. 2005 Aug;6(8):852.

PMID:
15951814
18.

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.

Dunn GP, Sheehan KC, Old LJ, Schreiber RD.

Cancer Res. 2005 Apr 15;65(8):3447-53.

19.

IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation.

Krug A, Uppaluri R, Facchetti F, Dorner BG, Sheehan KC, Schreiber RD, Cella M, Colonna M.

J Immunol. 2002 Dec 1;169(11):6079-83.

20.

A completely foreign receptor can mediate an interferon-gamma-like response.

Strobl B, Arulampalam V, Is'harc H, Newman SJ, Schlaak JF, Watling D, Costa-Pereira AP, Schaper F, Behrmann I, Sheehan KC, Schreiber RD, Horn F, Heinrich PC, Kerr IM.

EMBO J. 2001 Oct 1;20(19):5431-42.

22.

Baculovirus stimulates antiviral effects in mammalian cells.

Gronowski AM, Hilbert DM, Sheehan KC, Garotta G, Schreiber RD.

J Virol. 1999 Dec;73(12):9944-51.

23.

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.

Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM Jr, Schreiber RD.

Cell. 1998 May 1;93(3):373-83.

24.

Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells.

Pinckard JK, Sheehan KC, Schreiber RD.

J Biol Chem. 1997 Apr 18;272(16):10784-9.

25.

Constitutive shedding of both p55 and p75 murine TNF receptors in vivo.

Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD.

J Immunol. 1997 Apr 15;158(8):3869-73.

PMID:
9103455
26.
27.

Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.

Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD.

Cell. 1996 Feb 9;84(3):431-42.

28.

Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2.

Mnich SJ, Veenhuizen AW, Monahan JB, Sheehan KC, Lynch KR, Isakson PC, Portanova JP.

J Immunol. 1995 Nov 1;155(9):4437-44.

PMID:
7594605
29.

Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75.

Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD.

J Exp Med. 1995 Feb 1;181(2):607-17.

30.

Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice.

Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KC, Schreiber RD, Goeddel DV, Moore MW.

Nature. 1994 Dec 8;372(6506):560-3.

PMID:
7990930
31.
32.

Tumor necrosis factor-alpha prevents rejection of islet xenografts (rat to mouse).

Gerasimidi A, Sheehan KC, Schreiber RD, Lacy PE.

Diabetes. 1993 May;42(5):651-7.

PMID:
8482422
33.

Prevention of rejection of transforming growth factor beta-treated rat-to-mouse islet xenografts by monoclonal antibody to tumor necrosis factor.

Carel JC, Sheehan KC, Schreiber RD, Lacy PE.

Transplantation. 1993 Feb;55(2):456-8. No abstract available.

PMID:
8434409
34.

Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice.

Rogers HW, Sheehan KC, Brunt LM, Dower SK, Unanue ER, Schreiber RD.

Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1011-5.

35.

Generation of monoclonal antibodies to murine IL-1 beta and demonstration of IL-1 in vivo.

Hogquist KA, Nett MA, Sheehan KC, Pendleton KD, Schreiber RD, Chaplin DD.

J Immunol. 1991 Mar 1;146(5):1534-40.

PMID:
1993843
36.

The regulation of murine B cell differentiation. I. Nonspecific suppression caused by Mycoplasma arginini.

Foresman MD, Sheehan KC, Swierkosz JE.

Cell Immunol. 1989 Oct 15;123(2):354-72.

PMID:
2790965
37.

Enumeration of cytokine-secreting cells at the single-cell level.

Skidmore BJ, Stamnes SA, Townsend K, Glasebrook AL, Sheehan KC, Schreiber RD, Chiller JM.

Eur J Immunol. 1989 Sep;19(9):1591-7.

PMID:
2507324
38.

Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice.

Bancroft GJ, Sheehan KC, Schreiber RD, Unanue ER.

J Immunol. 1989 Jul 1;143(1):127-30.

PMID:
2499625
39.

Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha.

Shalaby MR, Fendly B, Sheehan KC, Schreiber RD, Ammann AJ.

Transplantation. 1989 Jun;47(6):1057-61.

PMID:
2525289
40.

Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.

Sheehan KC, Ruddle NH, Schreiber RD.

J Immunol. 1989 Jun 1;142(11):3884-93.

PMID:
2469726
41.

Monoclonal antibodies to murine IL-1 alpha. Production, characterization, and inhibition of membrane-associated IL-1 activity.

Fuhlbrigge RC, Sheehan KC, Schreiber RD, Chaplin DD, Unanue ER.

J Immunol. 1988 Oct 15;141(8):2643-50.

PMID:
3262667
42.

Purification and characterization of the human interferon-gamma receptor from placenta.

Calderon J, Sheehan KC, Chance C, Thomas ML, Schreiber RD.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4837-41.

43.

Generation and characterization of monoclonal antibodies specific for the human IFN-gamma receptor.

Sheehan KC, Calderon J, Schreiber RD.

J Immunol. 1988 Jun 15;140(12):4231-7.

PMID:
2453573

Supplemental Content

Loading ...
Support Center